Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tumor necrosis factor α (TNF-α) is a well-recognized proinflammatory cytokine, and as such provides an ideal target for anti-inflammatory therapies. Recent developments have shown very exciting results, and in this article, Jan Bondeson, Marc Feldman, and Ravinder N. Maini review the outcome of clinical trials of anti-TNF-α therapies in a range of chronic inflammatory diseases.

Type

Journal article

Journal

Immunologist

Publication Date

01/12/2000

Volume

8

Pages

136 - 140